These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17169256)

  • 1. Prostate-specific antigen 'velocity' as a diagnostic test for prostate cancer.
    Concato J; Wells CK
    J Investig Med; 2006 Nov; 54(7):361-4. PubMed ID: 17169256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
    Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
    Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
    Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
    J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
    Carter HB; Ferrucci L; Kettermann A; Landis P; Wright EJ; Epstein JI; Trock BJ; Metter EJ
    J Natl Cancer Inst; 2006 Nov; 98(21):1521-7. PubMed ID: 17077354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer.
    Thiel R; Pearson JD; Epstein JI; Walsh PC; Carter HB
    Urology; 1997 May; 49(5):716-20. PubMed ID: 9145976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
    Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer screening with prostate-specific antigen in hemodialysis patients.
    Horinaga M; Kitamura K; Saito S; Ukimura O; Nakanoma T; Okihara K; Kitagawa M; Nakanishi H; Miki T
    Urol Int; 2007; 78(4):334-7. PubMed ID: 17495492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
    Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
    BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
    Loeb S; Roehl KA; Catalona WJ; Nadler RB
    J Urol; 2007 Mar; 177(3):899-902. PubMed ID: 17296371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
    Eggener SE; Roehl KA; Catalona WJ
    J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of delayed clinician response to elevated prostate-specific antigen values.
    Nepple KG; Joudi FN; Hillis SL; Wahls TL
    Mayo Clin Proc; 2008 Apr; 83(4):439-45. PubMed ID: 18380989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection.
    Smith DS; Catalona WJ
    J Urol; 1994 Oct; 152(4):1163-7. PubMed ID: 7520949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive properties of serum-prostate-specific antigen testing in a community-based setting.
    Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM
    Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
    King CR; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
    Urology; 2007 Apr; 69(4):732-7. PubMed ID: 17445660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.